VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
ATRAAtara Biotherapeutics, Inc.
$10.07$91M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksATRAEarnings History

ATRA logoAtara Biotherapeutics, Inc. (ATRA) Earnings History

Net Loss

14 years of earnings data (2012–2025) · Currently unprofitable on a TTM basis

TTM Net Income
-$9M
● Net Loss
TTM EPS (Diluted)
$-0.67
Per share, diluted
YoY EPS Growth
+122.5%
Excellent
Net Margin
27.1%
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating Margin29.7%
Gross Margin82.4%
Return on EquityN/A
Return on Assets50.5%
Record Annual Net Income$33MFY2025
Record Quarterly EPS$4.50Q2 2022
Consecutive Profitable Years1years
Q1 2026
Net Income-$4M
EPS (Diluted)$-0.29
YoY Growth+122.5%Excellent
QoQ Growth-21.7%Declining

Loading earnings history...

Atara Biotherapeutics, Inc. (ATRA) Earnings Overview

As of June 22, 2026, Atara Biotherapeutics, Inc. (ATRA) reported trailing twelve-month net income of -$9M, reflecting +122.5% year-over-year growth. The company earned $-0.67 per diluted share over the past four quarters, with a net profit margin of 27.1%.

Looking at the long-term picture, ATRA's historical earnings data spans multiple years. The company achieved its highest annual net income of $33M in fiscal 2025, representing a new all-time high.

Atara Biotherapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including FATE (-$130M net income, -2051.1% margin), ADCT (-$137M net income, -175.3% margin), CABA (-$175M net income), ATRA has outperformed on profitability metrics. Compare ATRA vs FATE →

ATRA Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
ATRA logoATRACurrent
-$9M$-0.6727.1%-+122.5%—
FATE logoFATE
-$130M$-1.08-2051.1%-51.8%+29.9%
ADCT logoADCT
-$137M$-0.89-175.3%-+30.9%
CABA logoCABA
-$175M$-1.57--127.0%+29.9%
IMVT logoIMVT
-$506M$-2.48--64.8%-1.5%
RCUS logoRCUS
-$369M$-2.94-142.9%-63.3%-4.8%
Best in group
Lowest in group

ATRA Historical Earnings Data (2012–2025)

14 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025$33M+138.3%$36M$2.5727.1%29.7%
2024-$85M+69.1%-$83M$-11.41-66.2%-64.7%
2023-$276M-20.9%-$276M$-65.18-3220.9%-3219.5%
2022-$228M+32.9%-$281M$-55.96-359.1%-441.2%
2021-$340M-10.9%-$340M$-90.78-1672.3%-1673.9%
2020-$307M-5.4%-$309M$-103.63--
2019-$291M+87.4%-$296M$-141.78--
2018-$2.31B-93.1%-$237M$-131.64--
2017-$1.19B-51.2%-$122M$-100.03--
2016-$790M-38.1%-$81M$-68.78--
2015-$572M-104.3%-$58M$-55.92--
2014-$280M-219.2%-$28M$-140.42--
2013-$88M+28.8%-$9M$-227.09--
2012-$123M--$3M$-16.81--

Download Data

Export ATRA earnings history in CSV or JSON format

Free sign-in required to download data

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

14+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

ATRA — Frequently Asked Questions

Quick answers to the most common questions about buying ATRA stock.

What is ATRA earnings per share (EPS)?

ATRA trailing twelve-month (TTM) diluted EPS is $-0.67, reflecting +122.5% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2012 to 2025 is available in the table on this page.

What is Atara Biotherapeutics, Inc.'s net income?

Atara Biotherapeutics, Inc. (ATRA) trailing twelve-month net income is $-9M as of 2025. Earnings grew +122.5% year-over-year.

Is ATRA profitable?

ATRA is not currently profitable on a TTM basis, reporting a net loss of $-9M. Net margin is +27.1%. Investors should monitor for a return to profitability.

What is ATRA's earnings growth rate?

ATRA compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2012 to 2025.

What are ATRA's profit margins?

Atara Biotherapeutics, Inc. net profit margin is +27.1%, operating margin is +29.7%, and gross margin is +82.4%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is N/A.

Is ATRA growing earnings?

Yes, ATRA earnings are accelerating — EPS growth of +122.5% exceeds the 5-year CAGR of N/A. TTM net income reached $-9M. Earnings momentum is strengthening.

What was ATRA's best earnings year?

Atara Biotherapeutics, Inc.'s highest annual net income on record is $33M, achieved in fiscal year 2025. Earnings history on this page spans 2012 to 2025 and includes all annual and quarterly figures.

What were ATRA's earnings last quarter?

ATRA's most recent reported quarter was Q1 2026. Net income was $-4M with diluted EPS of $-0.29. For a full breakdown of all quarters, see the quarterly earnings table on this page.

ATRA Earnings Over Time (2012–2025)

Net income & EPS — annual and quarterly view